Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 98 entries
Sorted by: Best Match Show Resources per page
Corrigendum: Hypogonadism and Sexual Dysfunction in Testicular Tumor Survivors: A Systematic Review.

Frontiers in endocrinology

La Vignera S, Cannarella R, Duca Y, Barbagallo F, Burgio G, Compagnone M, Di Cataldo A, Calogero AE, Condorelli RA.
PMID: 31258516
Front Endocrinol (Lausanne). 2019 Jun 19;10:393. doi: 10.3389/fendo.2019.00393. eCollection 2019.

[This corrects the article DOI: 10.3389/fendo.2019.00264.].

Cite
La Vignera S, Cannarella R, Duca Y, et al. Corrigendum: Hypogonadism and Sexual Dysfunction in Testicular Tumor Survivors: A Systematic Review. Front Endocrinol (Lausanne). 2019;10:393doi: 10.3389/fendo.2019.00393.
La Vignera, S., Cannarella, R., Duca, Y., Barbagallo, F., Burgio, G., Compagnone, M., Di Cataldo, A., Calogero, A. E., & Condorelli, R. A. (2019). Corrigendum: Hypogonadism and Sexual Dysfunction in Testicular Tumor Survivors: A Systematic Review. Frontiers in endocrinology, 10393. https://doi.org/10.3389/fendo.2019.00393
La Vignera, Sandro, et al. "Corrigendum: Hypogonadism and Sexual Dysfunction in Testicular Tumor Survivors: A Systematic Review." Frontiers in endocrinology vol. 10 (2019): 393. doi: https://doi.org/10.3389/fendo.2019.00393
La Vignera S, Cannarella R, Duca Y, Barbagallo F, Burgio G, Compagnone M, Di Cataldo A, Calogero AE, Condorelli RA. Corrigendum: Hypogonadism and Sexual Dysfunction in Testicular Tumor Survivors: A Systematic Review. Front Endocrinol (Lausanne). 2019 Jun 19;10:393. doi: 10.3389/fendo.2019.00393. eCollection 2019. PMID: 31258516; PMCID: PMC6594464.
Copy Download .nbib Format: NLM
TSH lowering effects of metformin: a possible mechanism of action.

Journal of endocrinological investigation

Cannarella R, Condorelli RA, Barbagallo F, Aversa A, Calogero AE, La Vignera S.
PMID: 33058005
J Endocrinol Invest. 2021 Jul;44(7):1547-1550. doi: 10.1007/s40618-020-01445-9. Epub 2020 Oct 14.

Preliminary clinical evidence suggests that metformin has TSH lowering effects in patients with T2DM and hypothyroidism or in those with TSH serum levels in the upper normal value. Also, metformin may exert a protective role against thyroid nodules growth...

Cite
Cannarella R, Condorelli RA, Barbagallo F, et al. TSH lowering effects of metformin: a possible mechanism of action. J Endocrinol Invest. 2020;44(7):1547-1550doi: 10.1007/s40618-020-01445-9.
Cannarella, R., Condorelli, R. A., Barbagallo, F., Aversa, A., Calogero, A. E., & La Vignera, S. (2021). TSH lowering effects of metformin: a possible mechanism of action. Journal of endocrinological investigation, 44(7), 1547-1550. https://doi.org/10.1007/s40618-020-01445-9
Cannarella, R, et al. "TSH lowering effects of metformin: a possible mechanism of action." Journal of endocrinological investigation vol. 44,7 (2021): 1547-1550. doi: https://doi.org/10.1007/s40618-020-01445-9
Cannarella R, Condorelli RA, Barbagallo F, Aversa A, Calogero AE, La Vignera S. TSH lowering effects of metformin: a possible mechanism of action. J Endocrinol Invest. 2021 Jul;44(7):1547-1550. doi: 10.1007/s40618-020-01445-9. Epub 2020 Oct 14. PMID: 33058005; PMCID: PMC8195970.
Copy Download .nbib Format: NLM
Combined Effects of the .

The world journal of men's health

Cannarella R, Musso N, Condorelli RA, Musmeci M, Stefani S, La Vignera S, Calogero AE.
PMID: 33151046
World J Mens Health. 2021 Jul;39(3):516-525. doi: 10.5534/wjmh.200070. Epub 2020 Sep 28.

PURPOSE: The aim of this study was to evaluate the combined effect of MATERIALS AND METHODS: One-hundred thirty Sicilian men were enrolled and underwent blood withdrawal for hormone measurement and RESULTS: No genotype of the CONCLUSIONS: The SNPs

Cite
Cannarella R, Musso N, Condorelli RA, et al. Combined Effects of the . World J Mens Health. 2020;39(3):516-525doi: 10.5534/wjmh.200070.
Cannarella, R., Musso, N., Condorelli, R. A., Musmeci, M., Stefani, S., La Vignera, S., & Calogero, A. E. (2021). Combined Effects of the . The world journal of men's health, 39(3), 516-525. https://doi.org/10.5534/wjmh.200070
Cannarella, Rossella, et al. "Combined Effects of the ." The world journal of men's health vol. 39,3 (2021): 516-525. doi: https://doi.org/10.5534/wjmh.200070
Cannarella R, Musso N, Condorelli RA, Musmeci M, Stefani S, La Vignera S, Calogero AE. Combined Effects of the . World J Mens Health. 2021 Jul;39(3):516-525. doi: 10.5534/wjmh.200070. Epub 2020 Sep 28. PMID: 33151046; PMCID: PMC8255408.
Copy Download .nbib Format: NLM
Metabolism and Ovarian Function in PCOS Women: A Therapeutic Approach with Inositols.

International journal of endocrinology

Laganà AS, Rossetti P, Buscema M, La Vignera S, Condorelli RA, Gullo G, Granese R, Triolo O.
PMID: 27579037
Int J Endocrinol. 2016;2016:6306410. doi: 10.1155/2016/6306410. Epub 2016 Aug 04.

Polycystic ovary syndrome (PCOS) is characterized by chronical anovulation and hyperandrogenism which may be present in a different degree of severity. Insulin-resistance and hyperinsulinemia are the main physiopathological basis of this syndrome and the failure of inositol-mediated signaling may...

Cite
Laganà AS, Rossetti P, Buscema M, et al. Metabolism and Ovarian Function in PCOS Women: A Therapeutic Approach with Inositols. Int J Endocrinol. 2016;2016:6306410doi: 10.1155/2016/6306410.
Laganà, A. S., Rossetti, P., Buscema, M., La Vignera, S., Condorelli, R. A., Gullo, G., Granese, R., & Triolo, O. (2016). Metabolism and Ovarian Function in PCOS Women: A Therapeutic Approach with Inositols. International journal of endocrinology, 20166306410. https://doi.org/10.1155/2016/6306410
Laganà, Antonio Simone, et al. "Metabolism and Ovarian Function in PCOS Women: A Therapeutic Approach with Inositols." International journal of endocrinology vol. 2016 (2016): 6306410. doi: https://doi.org/10.1155/2016/6306410
Laganà AS, Rossetti P, Buscema M, La Vignera S, Condorelli RA, Gullo G, Granese R, Triolo O. Metabolism and Ovarian Function in PCOS Women: A Therapeutic Approach with Inositols. Int J Endocrinol. 2016;2016:6306410. doi: 10.1155/2016/6306410. Epub 2016 Aug 04. PMID: 27579037; PMCID: PMC4989075.
Copy Download .nbib Format: NLM
SARS-CoV-2: the endocrinological protective clinical model derived from patients with prostate cancer.

Therapeutic advances in endocrinology and metabolism

La Vignera S, Cannarella R, Condorelli RA, Torre F, Aversa A, Calogero AE.
PMID: 32699587
Ther Adv Endocrinol Metab. 2020 Jul 11;11:2042018820942385. doi: 10.1177/2042018820942385. eCollection 2020.

No abstract available.

Cite
La Vignera S, Cannarella R, Condorelli RA, et al. SARS-CoV-2: the endocrinological protective clinical model derived from patients with prostate cancer. Ther Adv Endocrinol Metab. 2020;11:2042018820942385doi: 10.1177/2042018820942385.
La Vignera, S., Cannarella, R., Condorelli, R. A., Torre, F., Aversa, A., & Calogero, A. E. (2020). SARS-CoV-2: the endocrinological protective clinical model derived from patients with prostate cancer. Therapeutic advances in endocrinology and metabolism, 112042018820942385. https://doi.org/10.1177/2042018820942385
La Vignera, Sandro, et al. "SARS-CoV-2: the endocrinological protective clinical model derived from patients with prostate cancer." Therapeutic advances in endocrinology and metabolism vol. 11 (2020): 2042018820942385. doi: https://doi.org/10.1177/2042018820942385
La Vignera S, Cannarella R, Condorelli RA, Torre F, Aversa A, Calogero AE. SARS-CoV-2: the endocrinological protective clinical model derived from patients with prostate cancer. Ther Adv Endocrinol Metab. 2020 Jul 11;11:2042018820942385. doi: 10.1177/2042018820942385. eCollection 2020. PMID: 32699587; PMCID: PMC7357014.
Copy Download .nbib Format: NLM
Early Identification of Isolated Sertoli Cell Dysfunction in Prepubertal and Transition Age: Is It Time?.

Journal of clinical medicine

La Vignera S, Condorelli RA, Cimino L, Cannarella R, Giacone F, Calogero AE.
PMID: 31075862
J Clin Med. 2019 May 09;8(5). doi: 10.3390/jcm8050636.

The male transitional phase is of fundamental importance for future fertility. This aspect is largely neglected in clinical practice. This opinion aims to shed light on these issues. The children frequently complete the transition phase with a slight reduction...

Cite
La Vignera S, Condorelli RA, Cimino L, et al. Early Identification of Isolated Sertoli Cell Dysfunction in Prepubertal and Transition Age: Is It Time?. J Clin Med. 2019;8(5)doi: 10.3390/jcm8050636.
La Vignera, S., Condorelli, R. A., Cimino, L., Cannarella, R., Giacone, F., & Calogero, A. E. (2019). Early Identification of Isolated Sertoli Cell Dysfunction in Prepubertal and Transition Age: Is It Time?. Journal of clinical medicine, 8(5), . https://doi.org/10.3390/jcm8050636
La Vignera, Sandro, et al. "Early Identification of Isolated Sertoli Cell Dysfunction in Prepubertal and Transition Age: Is It Time?." Journal of clinical medicine vol. 8,5 (2019). doi: https://doi.org/10.3390/jcm8050636
La Vignera S, Condorelli RA, Cimino L, Cannarella R, Giacone F, Calogero AE. Early Identification of Isolated Sertoli Cell Dysfunction in Prepubertal and Transition Age: Is It Time?. J Clin Med. 2019 May 09;8(5). doi: 10.3390/jcm8050636. PMID: 31075862; PMCID: PMC6572413.
Copy Download .nbib Format: NLM
Poor Efficacy of L-Acetylcarnitine in the Treatment of Asthenozoospermia in Patients with Type 1 Diabetes.

Journal of clinical medicine

Condorelli RA, Calogero AE, Cannarella R, Giacone F, Mongioi' LM, Cimino L, Aversa A, La Vignera S.
PMID: 31035375
J Clin Med. 2019 Apr 28;8(5). doi: 10.3390/jcm8050585.

No abstract available.

Cite
Condorelli RA, Calogero AE, Cannarella R, et al. Poor Efficacy of L-Acetylcarnitine in the Treatment of Asthenozoospermia in Patients with Type 1 Diabetes. J Clin Med. 2019;8(5)doi: 10.3390/jcm8050585.
Condorelli, R. A., Calogero, A. E., Cannarella, R., Giacone, F., Mongioi', L. M., Cimino, L., Aversa, A., & La Vignera, S. (2019). Poor Efficacy of L-Acetylcarnitine in the Treatment of Asthenozoospermia in Patients with Type 1 Diabetes. Journal of clinical medicine, 8(5), . https://doi.org/10.3390/jcm8050585
Condorelli, Rosita A, et al. "Poor Efficacy of L-Acetylcarnitine in the Treatment of Asthenozoospermia in Patients with Type 1 Diabetes." Journal of clinical medicine vol. 8,5 (2019). doi: https://doi.org/10.3390/jcm8050585
Condorelli RA, Calogero AE, Cannarella R, Giacone F, Mongioi' LM, Cimino L, Aversa A, La Vignera S. Poor Efficacy of L-Acetylcarnitine in the Treatment of Asthenozoospermia in Patients with Type 1 Diabetes. J Clin Med. 2019 Apr 28;8(5). doi: 10.3390/jcm8050585. PMID: 31035375; PMCID: PMC6572264.
Copy Download .nbib Format: NLM
Hypogonadism and Sexual Dysfunction in Testicular Tumor Survivors: A Systematic Review.

Frontiers in endocrinology

La Vignera S, Cannarella R, Duca Y, Barbagallo F, Burgio G, Compagnone M, Di Cataldo A, Calogero AE, Condorelli RA.
PMID: 31133982
Front Endocrinol (Lausanne). 2019 May 07;10:264. doi: 10.3389/fendo.2019.00264. eCollection 2019.

Testicular tumor is the most common malignancy in men of reproductive age. According to the tumor histology and staging, current treatment options include orchiectomy alone or associated with adjuvant chemo- and/or radiotherapy. Although these treatments have considerably raised the...

Cite
La Vignera S, Cannarella R, Duca Y, et al. Hypogonadism and Sexual Dysfunction in Testicular Tumor Survivors: A Systematic Review. Front Endocrinol (Lausanne). 2019;10:264doi: 10.3389/fendo.2019.00264.
La Vignera, S., Cannarella, R., Duca, Y., Barbagallo, F., Burgio, G., Compagnone, M., Di Cataldo, A., Calogero, A. E., & Condorelli, R. A. (2019). Hypogonadism and Sexual Dysfunction in Testicular Tumor Survivors: A Systematic Review. Frontiers in endocrinology, 10264. https://doi.org/10.3389/fendo.2019.00264
La Vignera, Sandro, et al. "Hypogonadism and Sexual Dysfunction in Testicular Tumor Survivors: A Systematic Review." Frontiers in endocrinology vol. 10 (2019): 264. doi: https://doi.org/10.3389/fendo.2019.00264
La Vignera S, Cannarella R, Duca Y, Barbagallo F, Burgio G, Compagnone M, Di Cataldo A, Calogero AE, Condorelli RA. Hypogonadism and Sexual Dysfunction in Testicular Tumor Survivors: A Systematic Review. Front Endocrinol (Lausanne). 2019 May 07;10:264. doi: 10.3389/fendo.2019.00264. eCollection 2019. PMID: 31133982; PMCID: PMC6513875.
Copy Download .nbib Format: NLM
Thyroid Hormones and Spermatozoa: In VitroEffects on Sperm Mitochondria, Viability and DNA Integrity.

Journal of clinical medicine

Condorelli RA, La Vignera S, Mongioì LM, Alamo A, Giacone F, Cannarella R, Calogero AE.
PMID: 31137924
J Clin Med. 2019 May 27;8(5). doi: 10.3390/jcm8050756.

The aim of this study wasto assess the in vitro effects of levothyroxine (LT4) on conventional and bio-functional sperm parameters and its implications on fertility. Patients with male idiopathic infertility were enrolled and subjected to examination of the seminal...

Cite
Condorelli RA, La Vignera S, Mongioì LM, et al. Thyroid Hormones and Spermatozoa: In VitroEffects on Sperm Mitochondria, Viability and DNA Integrity. J Clin Med. 2019;8(5)doi: 10.3390/jcm8050756.
Condorelli, R. A., La Vignera, S., Mongioì, L. M., Alamo, A., Giacone, F., Cannarella, R., & Calogero, A. E. (2019). Thyroid Hormones and Spermatozoa: In VitroEffects on Sperm Mitochondria, Viability and DNA Integrity. Journal of clinical medicine, 8(5), . https://doi.org/10.3390/jcm8050756
Condorelli, Rosita A, et al. "Thyroid Hormones and Spermatozoa: In VitroEffects on Sperm Mitochondria, Viability and DNA Integrity." Journal of clinical medicine vol. 8,5 (2019). doi: https://doi.org/10.3390/jcm8050756
Condorelli RA, La Vignera S, Mongioì LM, Alamo A, Giacone F, Cannarella R, Calogero AE. Thyroid Hormones and Spermatozoa: In VitroEffects on Sperm Mitochondria, Viability and DNA Integrity. J Clin Med. 2019 May 27;8(5). doi: 10.3390/jcm8050756. PMID: 31137924; PMCID: PMC6571713.
Copy Download .nbib Format: NLM
Determinants of Early Response to Low-Intensity Extracorporeal Shockwaves for the Treatment of Vasculogenic Erectile Dysfunction: An Open-Label, Prospective Study.

Journal of clinical medicine

Vita R, Benvenga S, Giammusso B, La Vignera S.
PMID: 31336717
J Clin Med. 2019 Jul 11;8(7). doi: 10.3390/jcm8071017.

The aim of this study was to expand existing literature on the effects of cardiovascular risk factors on the outcome of low-intensity extracorporeal shockwaves therapy (LIESWT), and to evaluate the role of hormone concentrations. Twenty patients with long-standing, PDE5i-resistant,...

Cite
Vita R, Benvenga S, Giammusso B, et al. Determinants of Early Response to Low-Intensity Extracorporeal Shockwaves for the Treatment of Vasculogenic Erectile Dysfunction: An Open-Label, Prospective Study. J Clin Med. 2019;8(7)doi: 10.3390/jcm8071017.
Vita, R., Benvenga, S., Giammusso, B., & La Vignera, S. (2019). Determinants of Early Response to Low-Intensity Extracorporeal Shockwaves for the Treatment of Vasculogenic Erectile Dysfunction: An Open-Label, Prospective Study. Journal of clinical medicine, 8(7), . https://doi.org/10.3390/jcm8071017
Vita, Roberto, et al. "Determinants of Early Response to Low-Intensity Extracorporeal Shockwaves for the Treatment of Vasculogenic Erectile Dysfunction: An Open-Label, Prospective Study." Journal of clinical medicine vol. 8,7 (2019). doi: https://doi.org/10.3390/jcm8071017
Vita R, Benvenga S, Giammusso B, La Vignera S. Determinants of Early Response to Low-Intensity Extracorporeal Shockwaves for the Treatment of Vasculogenic Erectile Dysfunction: An Open-Label, Prospective Study. J Clin Med. 2019 Jul 11;8(7). doi: 10.3390/jcm8071017. PMID: 31336717; PMCID: PMC6678562.
Copy Download .nbib Format: NLM
D-Chiro-Inositol Improves Sperm Mitochondrial Membrane Potential: In Vitro Evidence.

Journal of clinical medicine

Condorelli RA, Barbagallo F, Calogero AE, Cannarella R, Crafa A, La Vignera S.
PMID: 32392776
J Clin Med. 2020 May 07;9(5). doi: 10.3390/jcm9051373.

The use of inositols in endocrinological clinical practice is increasingly widespread. Most of the existing evidence concerns myoinositol (MYO), the most abundant form in nature, especially in women with polycystic ovarian syndrome. We have previously shown that MYO increases...

Cite
Condorelli RA, Barbagallo F, Calogero AE, et al. D-Chiro-Inositol Improves Sperm Mitochondrial Membrane Potential: In Vitro Evidence. J Clin Med. 2020;9(5)doi: 10.3390/jcm9051373.
Condorelli, R. A., Barbagallo, F., Calogero, A. E., Cannarella, R., Crafa, A., & La Vignera, S. (2020). D-Chiro-Inositol Improves Sperm Mitochondrial Membrane Potential: In Vitro Evidence. Journal of clinical medicine, 9(5), . https://doi.org/10.3390/jcm9051373
Condorelli, Rosita A, et al. "D-Chiro-Inositol Improves Sperm Mitochondrial Membrane Potential: In Vitro Evidence." Journal of clinical medicine vol. 9,5 (2020). doi: https://doi.org/10.3390/jcm9051373
Condorelli RA, Barbagallo F, Calogero AE, Cannarella R, Crafa A, La Vignera S. D-Chiro-Inositol Improves Sperm Mitochondrial Membrane Potential: In Vitro Evidence. J Clin Med. 2020 May 07;9(5). doi: 10.3390/jcm9051373. PMID: 32392776; PMCID: PMC7290519.
Copy Download .nbib Format: NLM
Peroxisome Proliferator-Activated Receptor Modulation during Metabolic Diseases and Cancers: Master and Minions.

PPAR research

Vitale SG, Laganà AS, Nigro A, La Rosa VL, Rossetti P, Rapisarda AM, La Vignera S, Condorelli RA, Corrado F, Buscema M, D'Anna R.
PMID: 28115924
PPAR Res. 2016;2016:6517313. doi: 10.1155/2016/6517313. Epub 2016 Dec 28.

The prevalence of obesity and metabolic diseases (such as type 2 diabetes mellitus, dyslipidaemia, and cardiovascular diseases) has increased in the last decade, in both industrialized and developing countries. This also coincided with our observation of a similar increase...

Cite
Vitale SG, Laganà AS, Nigro A, et al. Peroxisome Proliferator-Activated Receptor Modulation during Metabolic Diseases and Cancers: Master and Minions. PPAR Res. 2016;2016:6517313doi: 10.1155/2016/6517313.
Vitale, S. G., Laganà, A. S., Nigro, A., La Rosa, V. L., Rossetti, P., Rapisarda, A. M., La Vignera, S., Condorelli, R. A., Corrado, F., Buscema, M., & D'Anna, R. (2016). Peroxisome Proliferator-Activated Receptor Modulation during Metabolic Diseases and Cancers: Master and Minions. PPAR research, 20166517313. https://doi.org/10.1155/2016/6517313
Vitale, Salvatore Giovanni, et al. "Peroxisome Proliferator-Activated Receptor Modulation during Metabolic Diseases and Cancers: Master and Minions." PPAR research vol. 2016 (2016): 6517313. doi: https://doi.org/10.1155/2016/6517313
Vitale SG, Laganà AS, Nigro A, La Rosa VL, Rossetti P, Rapisarda AM, La Vignera S, Condorelli RA, Corrado F, Buscema M, D'Anna R. Peroxisome Proliferator-Activated Receptor Modulation during Metabolic Diseases and Cancers: Master and Minions. PPAR Res. 2016;2016:6517313. doi: 10.1155/2016/6517313. Epub 2016 Dec 28. PMID: 28115924; PMCID: PMC5225385.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 98 entries